Citations

Mayo Clinic

Showing 10 of 108551 citations.

When a Surgical Colleague Makes an Error
Antiel, Ryan M. , Blinman, Thane A. , Rentea, Rebecca M. , Gonzalez, Katherine W. , Knott, E. Marty, Juang, David , Oyetunji, Tolulope A. , Holcomb, George, Lantos, John D. , Angelos, Peter

Pediatrics | February 4, 2016 | Volume: 137 | Issue: 3 | Pages: No page available

10.1542/peds.2015-3828 | PMID 26908678 Get It

Professionalism requires that doctors acknowledge their errors and figure out how to avoid making similar ones in the future. Over the last few decades, doctors have gotten better at acknowledging mistakes and apologizing to patients when a mistake happens. Such disclosure is especially complicated when one becomes aware of an error made by a colleague. We present a case in which consultant surgeons became aware that a colleague seemed to have made a serious error. Experts in surgery and bioethics comment on appropriate responses to this situation.
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
Ansell, Stephen M. , Villasboas, Jose Caetano, Villasboas, José C. , Witzig, Thomas E.

Oncotarget | February 3, 2016 | Volume: 7 | Issue: 11 | Pages: 13260-13264

10.18632/oncotarget.7177 | PMID 26848626 Get It

Clinical characteristics and outcomes in biclonal gammopathies
Mullikin, Trey C. , Dispenzieri, Angela , Lacy, Martha Q. , Lin, Yi , Dingli, David , Go, Ronald S. , Hayman, Suzanne R. , Zeldenrust, Steven R., Russell, Stephen J. , Lust, John A., Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Rajkumar, S. Vincent , Leung, Nelson , Gertz, Morie A. , Go, Ronald S , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

American Journal of Hematology | February 3, 2016 | Volume: 91 | Issue: 5 | Pages: 473-475

10.1002/ajh.24319 | PMID 26840395 Get It

A single monoclonal protein typically characterizes monoclonal gammopathies, but a small proportion may have more than one M protein identifiable. In the setting of symptomatic multiple myeloma (MM), the development of a new monoclonal protein following therapy is associated with better outcomes. As for the precursor conditions, monoclonal gammopathy undetermined significance (MGUS) and smoldering multiple myeloma (SMM), there is limited information on the impact of a second monoclonal protein on the disease course, including progression and response to treatment. The outcomes of patients with MGUS and SMM with more than one monoclonal protein, after identifying 539 patients with biclonal proteins on electrophoresis and/or immunofixation, were reported. About 22 of 393 patients with MGUS/biclonal gammopathy of undetermined significance (BGUS) progressed to SMM (6), MM (11), AL (3), or WM (2), and 5 of 16 patients with biclonal SMM progressed to MM. The rate of progression for BGUS was approximately 1% per year, which is similar to MGUS with one monoclonal protein. The median estimated time of progression of biclonal SMM was 2.6 years; similar to monoclonal SMM. For patients with biclonal MM, both M spikes responded to treatment and, upon relapse, the original dominant M protein remained dominant as the disease progressed. In conclusion, the presence of a second monoclonal protein does not appear to affect the progression of precursor states and suggests multiple monoclonal proteins do not clinically impact one another in the course of the disease. Am. J. Hematol. 91:473–475, 2016. © 2016 Wiley Periodicals, Inc.
A Novel Selectable Islet 1 Positive Progenitor Cell Reprogrammed to Expandable and Functional Smooth Muscle Cells
Turner, Elizabeth C., Huang, Chien‐Ling , Sawhney, Neha, Govindarajan, Kalaimathi, Clover, Anthony J. P., Martin, Kenneth, Browne, Tara C., Whelan, Derek , Kumar, Arun , Mackrill, John J. , Wang, Shaohua , Schmeckpeper, Jeffrey , Stocca, Alessia, Pierce, William Gamewell, Leblond, Anne‐Laure , Cai, Liquan , O’Sullivan, Donnchadh , Büneker, Chirlei Klein, Choi, Janet , MacSharry, John , Russell, Stephen J. , Caplice, Noel M. , Ikeda, Yasuhiro , Russell, Stephen J

Stem Cells | February 3, 2016 | Volume: 34 | Issue: 5 | Pages: 1354-1368

10.1002/stem.2319 | PMID 26840832 Get It

AbstractDisorders affecting smooth muscle structure/function may require technologies that can generate large scale, differentiated and contractile smooth muscle cells (SMC) suitable for cell therapy. To date no clonal precursor population that provides large numbers of differentiated SMC in culture has been identified in a rodent. Identification of such cells may also enhance insight into progenitor cell fate decisions and the relationship between smooth muscle precursors and disease states that implicate differentiated SMC. In this study, we used classic clonal expansion techniques to identify novel self-renewing Islet 1 (Isl-1) positive primitive progenitor cells (PPC) within rat bone marrow that exhibited canonical stem cell markers and preferential differentiation towards a smooth muscle-like fate. We subsequently used molecular tagging to select Isl-1 positive clonal populations from expanded and de novo marrow cell populations. We refer to these previously undescribed cells as the PPC given its stem cell marker profile, and robust self-renewal capacity. PPC could be directly converted into induced smooth muscle cells (iSMC) using single transcription factor (Kruppel-like factor 4) knockdown or transactivator (myocardin) overexpression in contrast to three control cells (HEK 293, endothelial cells and mesenchymal stem cells) where such induction was not possible. iSMC exhibited immuno- and cytoskeletal-phenotype, calcium signaling profile and contractile responses similar to bona fide SMC. Passaged iSMC could be expanded to a scale sufficient for large scale tissue replacement. PPC and reprogramed iSMC so derived may offer future opportunities to investigate molecular, structure/function and cell-based replacement therapy approaches to diverse cardiovascular, respiratory, gastrointestinal, and genitourinary diseases that have as their basis smooth muscle cell functional aberrancy or numerical loss.
Advanced Studies in Clinical and Experimental Research in Gastroenterology
Tachecí, Ilja , Varayil, Jithinraj Edakkanambeth , Zelinková, Zuzana , Kopáčová, Marcela , Zavoral, Miroslav , Edakkanambeth Varayil, Jithinraj, Edakkanambeth Varayil, Jithinraj

Gastroenterology Research and Practice | February 3, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-2

10.1155/2016/4253143 | PMID 26955389 Get It

Histopathological findings following pipeline embolization in a human cerebral aneurysm at the basilar tip
Kelly, Michael , Kadirvel, Ramanathan , Kallmes, David F. , Dai, Daying , Kallmes, David, Ding, Yonghong

Interventional Neuroradiology | February 3, 2016 | Volume: 22 | Issue: 2 | Pages: 153-157

10.1177/1591019915622165 | PMID 26842611 Get It

We report histopathological findings from a human cerebral aneurysm following treatment with a flow diverter. A 75-year-old male underwent flow diversion treatment (Pipeline Embolization Device (PED)) and coil embolization for treatment of an aneurysm at the basilar tip. At four months, angiography showed complete aneurysm occlusion; at 12 months angiography demonstrated that the aneurysm had reopened. The patient expired from brainstem compression. The aneurysm cavity was primarily filled with unorganized thrombus. Thick, interrupted neointima crossed the neck interface indicating blood flow into aneurysm through small channels. Along the parent artery the PED was covered by neointima having a measured thickness of 0.19 ± 0.01 mm; the maximal stenosis of the proximal parent artery was 27%. The perforating arteries that were crossed by the PED remained patent. Findings in this human case are similar to those in the elastase-induced aneurysms in rabbits.
Aging metabolism: Evitable or inevitable?
Lanza, Ian R. , Lanza, Ian R

Science Translational Medicine | February 3, 2016 | Volume: 8 | Issue: 324 | Pages: No page available

10.1126/scitranslmed.aaf2006 Get It

Lifestyle factors can explain many, but not all, of aging-related metabolic disturbances.
Evaluating the safety and the effects on colonic compliance of neostigmine during motility testing in patients with chronic constipation
Mouchli, Mohamad, Camilleri, Michael , Lee, T. , Parthasarathy, Gopanandan , Vijayvargiya, Prakhar , Halland, Magnus , Bharucha, Adil E. , Acosta, Andrés

Neurogastroenterology & Motility | February 3, 2016 | Volume: 28 | Issue: 6 | Pages: 871-878

10.1111/nmo.12786 | PMID 26840188 Get It

AbstractBackgroundNeostigmine, an acetyl cholinesterase inhibitor, stimulates colonic motor activity and may induce vagally mediated cardiovascular effects. Our aim was to evaluate effects of i.v. neostigmine on colonic compliance and its safety in patients with chronic constipation.MethodsWe retrospectively reviewed medical records of a selected group of 144 outpatients with chronic constipation who were refractory to treatment. These patients had undergone intracolonic motility and compliance measurements with an infinitely compliant balloon linked to a barostat. Data abstracted included barostat balloon mean volumes with increases in pressure (4 mmHg steps from 0 to 44 mmHg) before and after i.v. neostigmine. Vital signs and oxygen saturation before and after neostigmine were recorded.Key ResultsOf the 144 patients, 133 were female, mean age was 41.0 ± 15.4 years (SD), and duration of constipation was 12.9 ± 13.8 years. Among patients who had undergone colonic transit measurement by scintigraphy, the overall colonic transit at 24 h (geometric center, GC24 [n = 115]) was 1.5 ± 0.7 (normal >1.3), and at 48 h (GC48 [n = 75]) it was 2.3 ± 0.9 (normal >1.9). Neostigmine decreased colonic compliance at lower distension pressures (e.g., 12 and 20 mmHg [both p < 0.001]), but not at 40 mmHg. There were expected minor changes in vital signs in response to neostigmine in 144 patients; however, one patient developed unresponsiveness, significant bradycardia, hypotension, and muscular rigidity that responded to 400 mcg i.v. atropine.Conclusions & InferencesNeostigmine significantly decreases colonic compliance in patients with refractory chronic constipation. Symptomatic bradycardia in response to neostigmine should be promptly reversed with atropine.
Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Adenocarcinoma
Stauffer, John , Coppola, Alessandro , Mody, Kabir , Asbun, Horacio J. , A Stauffer, John

World Journal of Surgery | February 3, 2016 | Volume: 40 | Issue: 6 | Pages: 1477-1484

10.1007/s00268-016-3412-6 | PMID 26847665 Get It

AbstractBackgroundLaparoscopic distal pancreatectomy (LDP) has been shown to have short‐term benefits over open distal pancreatectomy (ODP). Its application for pancreatic ductal adenocarcinoma (PDAC) remains controversial.MethodsFrom 1995 to 2014, 72 patients underwent distal pancreatectomy for PDAC at a single institution and were included in the study. Postoperative and long‐term outcomes of patients undergoing LDP (n = 44) or ODP (n = 28) were compared.ResultsLDP was associated with less blood loss (332 vs. 874 mL, p = 0.0012) and lower transfusion rates than ODP (18.2 vs. 50 %, p = 0.0495). Operative time was similar (254 vs. 266 min) for LDP and ODP; five patients (11.4 %) required conversion to ODP. Pancreatic fistulas (13.6 vs. 7.1 %) and major complications (13.6 vs. 25 %), were similar between LDP and ODP, respectively. Length of hospital stay (5.1 vs. 9.4 days, p = 0.0001) and time to initiate adjuvant therapy (69.4 vs. 95.6 days, p = 0.0441) was shorter for LDP than ODP. Tumor characteristics were similar but LDP was associated with more resected lymph nodes than ODP (25.9 vs. 12.7, p = 0.0001). One‐, three‐, and five‐year survival rates were similar between LDP (69, 41, and 41 %, respectively) and ODP (78, 44, and 32 %, respectively).ConclusionLDP is associated with less blood loss and need for blood transfusion, shorter hospital stay, and faster time to initiate adjuvant therapy than ODP for patients with PDAC. Postoperative outcomes and long‐term survival are similar between the two groups. LDP appears to be safe in the treatment of patients with PDAC.
Rasburicase‐induced methemoglobinemia: case report, literature review, and proposed treatment algorithm
Sherwood, Garrett, Paschal, Rita, Adamski, Jill

Clinical Case Reports | February 3, 2016 | Volume: 4 | Issue: 4 | Pages: 315-319

10.1002/ccr3.495 | PMID 27099716 Get It

Key Clinical MessageRasburicase for the treatment of tumor lysis syndrome has been associated with hemolytic anemia and methemoglobinemia, usually in patients with G6PD deficiency. Risks and benefits should be considered prior to use of rasburicase in at‐risk patients. Methylene blue will worsen the hemolytic anemia in G6PD deficiency and should be avoided.